	Application No.	Applicant(s)	
Notice of Allowability	10/591,203	MAIER ET AL.	
	Examiner	Art Unit	
	S. Devi, Ph.D.	1645	
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF of the Office or upon petition by the applicant. See 37 CFR 1.313	ears on the cover sheet wi (OR REMAINS) CLOSED ir or other appropriate commu IGHTS. This application is s	th the correspondence address this application. If not included unication will be mailed in due course	e. <b>THIS</b> ne initiative
1. $\boxtimes$ This communication is responsive to <u>Applicant's amendment</u>	ent filed 12/22/10.		
2. The allowed claim(s) is/are claims 19, 21 and 24, now rend	umbered as claims 1, 2 and	3 respectivel <u>y</u> .	
3.  ☐ Acknowledgment is made of a claim for foreign priority under the composition of the priority documents have composition of the priority documents are composition of the priority documents of the priority documents of the priority documents of the priority documents have composition of the priority documents have composite the priority documents have composit	e been received. e been received in Application cuments have been received of this communication to file MENT of this application.  eitted. Note the attached EXA es reason(s) why the oath or est be submitted. son's Patent Drawing Review	n No  d in this national stage application from this national stage application from the requirem and the requirement and the requireme	nents
Paper No./Mail Date  Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t	.84(c)) should be written on t	ne drawings in the front (not the back)	of
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
<ul> <li>Attachment(s)</li> <li>1. ☐ Notice of References Cited (PTO-892)</li> <li>2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)</li> <li>3. ☑ Information Disclosure Statements (PTO/SB/08),</li></ul>	6. ⊠ Interview Sı Paper No./ 7. ⊠ Examiner's	formal Patent Application ummary (PTO-413), Mail Date <u>201101</u> . Amendment/Comment Statement of Reasons for Allowance	e

#### ATTACHMENT TO NOTICE OF ALLOWABILITY

### Continued Examination under 37 C.F.R 1.114

1) A request for continued examination under 37 C.F.R 1.114, including the fee set forth in 37 C.F.R 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 C.F.R 1.114, and the fee set forth in 37 C.F.R 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 C.F.R 1.114. Applicant's submission filed on 12/20/10 has been entered.

# **Applicant's Amendment**

**2)** Acknowledgment is made of Applicant's amendment filed 12/20/10 in response to the final Office Action mailed 07/21/10.

### **Examiner's Amendment**

3) An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicants, an amendment may be filed as provided by 37 C.F.R 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee. The authorization to prepare this Examiner's amendment was provided by attorney David Provence in a telephonic interview on 12 January 2011. See the attached interview summary.

The instant application has been amended as indicated below.

- (a) Claim 19 has been amended as indicated below:
- --Claim 19 (Currently amended). An isolated bacterium wherein said isolated bacterium is Salmonella typhimurium or Salmonella typhi, wherein the isolated bacterium does not express a functional NiFe hydrogenase protein, wherein the isolated bacterium comprises a deletion mutation to each of three NiFe hydrogenase genes present in the genome of the isolated bacterium, wherein each

mutation prevents the expression of the corresponding gene product, wherein the first deletion is flanked by nucleotides 1-136 and nucleotides 137-232 of SEQ ID NO: 7, wherein the second deletion is flanked by nucleotides 1-289 and nucleotides 290-518 of SEQ ID NO: 8, and wherein the third deletion is flanked by nucleotides 1-200 and nucleotides 201-333 of SEQ ID NO: 9.--

#### **Status of Claims**

**4)** Claims 1, 3, 5-8, 10-17, 20, 22 and 23 have been cancelled via the amendment filed 12/20/10.

Claims 19 and 21 have been amended via the amendment filed 12/20/10.

Claim 19 has been amended via this Examiner's amendment.

Claims 19, 21 and 24 are pending and are under prosecution.

## **Information Disclosure Statement**

5) Acknowledgment is made of Applicants' information disclosure statement filed 12/22/10. The information referred to therein has been considered and a signed copy of the same is attached to this Office Action.

## Rejection(s) Moot

- 6) The rejection of claims 3, 20 and 22 made in paragraph 8 of the Office Action mailed 07/21/10 under 35 U.S.C. § 112, second paragraph, as being indefinite, is moot in light of Applicant's cancellation of the claims.
- 7) The rejection of claims 1 and 5-8 made in paragraph 27 of the Office Action mailed 07/21/10 under 35 U.S.C § 102(b) as being anticipated by Kim et al. (Appl. Environ. Microbiol. 62: 1759-1763, 1996) as evidenced by Schlecht et al. (Naturwissenschaften 80: 9-17, 1993, abstract), is moot in light of Applicant's cancellation of the claims.

- 8) The rejection of claims 1, 3, 5, 6 and 20 made in paragraph 28 of the Office Action mailed 07/21/10 under 35 U.S.C. § 102(b) as being anticipated by Sawers et al. (J. Bacteriol. 168: 398-404, 1986, of record), is moot in light of Applicant's cancellation of the claims.
- 9) The rejection of claim 10 made in paragraph 30 of the Office Action mailed 07/21/10 under 35 U.S.C. § 103(a) as being unpatentable over Kim et al. (Appl. Environ. Microbiol. 62: 1759-1763, 1996) as applied to claims 7 and 1 and further in view of Raettig Hansujurgen (US 3651214 A, of record), is moot in light of Applicant's cancellation of the claim.

## Rejection(s) Withdrawn

**10)** The rejection of claims 19 and 21 made in paragraph 25 of the Office Action mailed 07/21/10 under 35 U.S.C. § 112, second paragraph, as being indefinite, is withdrawn in light of Applicants' amendment to the claim.

#### Remarks

- **11)** Claims 19, 21 and 24, now renumbered as claims 1, 2 and 3 respectively, are allowed.
- **12)** Papers related to this application may be submitted to Group 1600, AU 1645 by facsimile transmission. The Fax number for submission of amendments, responses and/or papers is (571) 273-8300, which receives transmissions 24 hours a day and 7 days a week.
- 13) Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAG or Public PAIR. Status information for unpublished applications is available through Private PAIR

Application/Control No. 10591203

Art Unit: 1645 January, 2011

only. For more information about the PAIR system, see http://pair-direct.uspto.Mov.

Should you have questions on access to the Private PAA system, contact the

Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like

assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (in USA or CANADA) or 571-272-1000.

**14)** Any inquiry concerning this communication or earlier communications from

the Examiner should be directed to S. Devi, Ph.D., whose telephone number is (571)

272-0854. A message may be left on the Examiner's voice mail system. The

Examiner can normally be reached on Monday to Friday from 7.15 a.m. to 4.15 p.m.

except one day each bi-week, which would be disclosed on the Examiner's voice mail

system.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's

acting supervisor, Patricia Duffy, can be reached at (571)-272-0855.

/S. Devi/

**Primary Examiner** 

AU 1645

January, 2011

5